Evidence map›Paper›PMID 33022474›Full record

ArticleNeurobiology of aging2020

Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI.

Sheelakumari Raghavan, Scott A Przybelski, Robert I Reid, Jonathan Graff-Radford, Timothy G Lesnick, Samantha M Zuk, David S Knopman, Mary M Machulda, Michelle M Mielke, Ronald C Petersen and 2 more

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Language laterality and cognitive skills: does anatomy matter?Cerebral cortex (New York, N.Y. : 1991) · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Plasma NfL and GFAP for predicting VCI and related brain changes in community and clinical cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Vascular risk, gait, behavioral, and plasma indicators of VCID.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Sheelakumari RaghavanDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Scott A PrzybelskiHealth Sciences Research, Mayo Clinic, Rochester, MN, USA.
Robert I ReidInformation Technology, Mayo Clinic, Rochester, MN, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Timothy G LesnickHealth Sciences Research, Mayo Clinic, Rochester, MN, USA.
Samantha M ZukDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Mary M MachuldaDepartment of Psychology, Mayo Clinic, Rochester, MN, USA.
Michelle M MielkeHealth Sciences Research, Mayo Clinic, Rochester, MN, USA; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address: vemuri.prashanthi@mayo.edu.
Mayo Clinic in Arizona · USMayo Clinic in Florida · USMayo Clinic · US

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI John Lucas · 2019 to 2026
$33.5M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Investigating Resistance and Resilience Mechanisms in Alzheimer’s DiseaseR01AG056366 · NIA · MAYO CLINIC ROCHESTER · PI PRASHANTHI VEMURI · 2017 to 2026
$7.0M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
Development, Validation, and Application of an Imaging based CVD ScaleR01NS097495 · NINDS · MAYO CLINIC ROCHESTER · PI VEMURI, PRASHANTHI · 2016 to 2020
$2.9M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
EXTRAMURAL RES FACIL IMPROVEMENT PROG: POLYCYSTIC KIDNEY DISEASE, RENAL STUDIES,C06RR018898 · NCRR · MAYO CLINIC · PI BURNETT, JOHN C · 2004 to 2004
$2.3M
NCRR NIH HHS C06 RR018898NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG056366NIA NIH HHS R33 AG058738NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786NINDS NIH HHS R01 NS097495
6 · The paper itself

Abstract

Our goal was to evaluate the utility of diffusion tensor imaging (DTI) for predicting future cognitive decline in mild cognitive impairment (MCI) in conjunction with Alzheimer's disease (AD) biomarkers (amyloid positron emission tomography and AD signature neurodegeneration) in 132 MCI individuals ≥60 year old with structural magnetic resonance imaging, DTI, amyloid positron emission tomography, and at least one clinical follow-up. We used mixed-effect models to evaluate the prognostic ability of fractional anisotropy of the genu of the corpus callosum (FA-Genu), as a cerebrovascular disease marker, for predicting cognitive decline along with AD biomarkers. We contrasted the value of white matter hyperintensities, a traditional cerebrovascular disease marker as well as FA in the hippocampal cingulum bundle with the FA-Genu models. FA-Genu significantly predicted cognitive decline even after accounting for AD biomarkers. WMH was not associated with cognitive decline in the model with both WMH and FA-Genu. DTI specifically FA-Genu provides unique complementary information to AD biomarkers and has significant utility for prediction of cognitive decline in MCI.

Indexed as

AnisotropyCognitionAgedAged, 80 and overAlzheimer DiseaseCerebrovascular DisordersCognitive DysfunctionCorpus CallosumDiffusion Tensor ImagingFemaleHumansMalePredictive Value of TestsCerebrovascular diseaseDiffusion tensor imagingGenu of the corpus callosumMild cognitive impairment

Identifiers

PMID33022474
PMCPMC7722208
OpenAlexW3084140371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.